Association between dipeptidyl peptidase-4 inhibitor drugs and risk of acute pancreatitis
A meta-analysis
Shimin Chen, MDa, Enfa Zhao, MDb, Wenfei Li, MDc, Jiehong Wang, MDa,*

Abstract
Background: Previous studies have reported conflicting results for the relationship between dipeptidyl peptidase-4 (DPP-4) inhibitor drugs and acute pancreatitis. The aim of this study was to investigate the association between DPP-4 inhibitors and an increased risk of acute pancreatitis using meta-analysis.

Methods: We conducted a comprehensive search in PubMed, Embase, Web of Science, and Cochrane library from inception to March 4, 2017. Original articles with data on DPP-4 inhibitors and acute pancreatitis were included. We used random-effects models or fixed-effects models to combine the relative risks (RRs), odds ratio (OR), and hazard ratio (HRs) with 95% confidence intervals (CIs) in randomized controlled studies, case–control study and cohort study, respectively.

Results: Five case–control studies, 5 randomized controlled studies, and 3 cohort studies were selected of the 451 retrieved abstracts. A higher risk of acute pancreatitis was observed with the following RR/OR and 95%CI: RR 1.67 (1.08–2.59) in randomized controlled studies and OR 1.45 (1.30–1.61) in case–control studies. However, the pooled HR of the 3 cohort studies failed to confirm this association.

Conclusion: There is a marginally higher risk of acute pancreatitis with DPP-4 inhibitors. However, this risk was not observed in cohort studies. Thus, further clinical trials are required to confirm this finding.

Abbreviations: CI = confidence intervals, DPP-4 = dipeptidyl peptidase-4, GLP-1 = glucagon-like peptide 1, HR = hazard ratio, OR = odds ratio, RR = relative risks.

Keywords: acute pancreatitis, dipeptidyl peptidase-4 inhibitor, meta-analysis

1. Introduction
Dipeptidyl peptidase-4 (DPP-4) inhibitors are incretin-based drugs widely used in the management of type 2 diabetes mellitus.1,2 By preventing glucagon-like peptide 1 (GLP-1) from rapid breakdown through inhibition of DPP-4, an enzyme responsible for metabolizing the gastrointestinal hormone GLP-1, the DPP-4 inhibitors enhances pancreatic endogenous insulin secretion and suppresses pancreatic glucagon secretion, resulting in the reduction blood glucose levels.3,4 Acute pancreatitis is a serious condition that often results in hospitalization and even death.5 There is a concern about DPP-4 inhibitors leading to acute pancreatitis in humans, although the evidence remains controversial.6–7 Some authors have reported that after adjustment for available confounders, the use of DPP-4 inhibitors was not associated with an increased risk of acute pancreatitis compared with control groups.8–10 Other studies yielded positive results. A study from Italy concluded that the reporting odds ratio (OR) was 1.86 (95% CI: 1.54–2.24) in a case–control study of 2625 cases and 156,601 noncases.11 Singh et al12 reported a higher increased risk for acute pancreatitis associated with the use of DPP-4 inhibitors in patients with type 2 diabetes mellitus with an OR of 2.02 (95% CI: 1.31–3.01) in a population-based case–control study. A study conducted in France in 2013 even reported an OR of 12.08 (95% CI: 7.30–20.0) for acute pancreatitis associated with the use of DPP-4 inhibitors (sitagliptin, vildagliptin, and saxagliptin).13 A previous study14 found that DPP-4 inhibitors were associated with an increased risk of acute pancreatitis with an RR of 1.57; however, the study only focused on randomized clinical trials. Previous studies on this association have yielded conflicting results owing to their limited statistical power. Thus, the main aim of our study was to perform a meta-analysis on the risk of acute pancreatitis in type 2 diabetes mellitus patients who used DPP-4 inhibitors compared with a placebo-controlled population.

2. Materials and methods
2.1. Data sources and search strategy
We performed a systematic literature search of PubMed, Embase, Web of Science, and Cochrane library from inception to March 4, 2017. Human studies that reported data on DPP-4 inhibitors and risk of acute pancreatitis were included without restriction on language. The overall search strategy referred to medical subject
heading terms and/or text words: (dipeptidyl peptidase-4 inhibitor or DPP-4 or sitagliptin or alogliptin or linagliptin or saxagliptin or vildagliptin) and (acute pancreatitis or pancreatitis). The reference lists of all included studies were also manually reviewed for potential studies. Abstracts and citations were screened independently by 2 authors. All the included articles need a further screening for full-text reports. Papers that only provided abstracts were also included if sufficient data were reported.

2.2. Inclusion and exclusion criteria
A study was included in the meta-analysis if it met the following criteria: (1) studies assessing DDP-4 inhibitors compared with placebo; (2) studies evaluating the association between DDP-4 inhibitors and risk of acute pancreatitis in patients with type 2 diabetes mellitus; (3) one of the outcomes is acute pancreatitis; and (4) studies with reference group. Editorials, letters, systematic reviews, comments, or reports lacking sufficient data were excluded. If the works were shared or duplicated in more than one study, the most recent publication was included. All identified papers were reviewed by 2 authors independently. Any disagreements were resolved by consensus with a third reviewer.

2.3. Data extraction
Two investigators independently extracted the following data from each study: First author, year of publication, country, study type, adjusted HR/OR, and type of DDP-4 inhibitors used. Disagreements were resolved by detailed discussion, consensus, and arbitration by the third author.

2.4. Statistical analysis
All statistical analyses were performed with stata version 11.0 software (StataCorp, College Station, TX). Relative risks (RRs), OR, or hazard ratio (HR) with 95% confidence interval (CI) were used to estimate the effect sizes. $I^2$ was used to describe the statistical heterogeneity among studies. $I^2 > 50\%$ was considered to exhibit severe heterogeneity. A random-effect model was used if $P > .05$ and $I^2 < 50\%$; otherwise, a fixed-effect model was selected. We used the Begg test (rank correlation method)\[15\] to evaluate the possible publication bias and a $P$ value of $<.1$ was considered as significant statistical publication bias. We performed meta-analyses when relevant data were available from at least 3 studies.

3. Results
3.1. Characteristics of the subjects in the included studies
Detailed studies retrieval procedures are summarized in Figure 1. A total of 451 references were preliminarily identified according to the search strategy. Two hundred eight-nine records remained after excluding 162 duplicate articles. We screened titles and
abstracts of all identified papers and 202 clearly irrelevant records were excluded. After reviewing the remaining articles in detail, 74 articles were excluded with reasons. Finally, 5 case-control studies, 5 randomized controlled studies, and 3 cohort studies were included in the study. The characteristics of the 13 studies\[1,2,7–13,16–19\] are presented in Table 1.

### 3.2. Meta-analysis results

As shown in Figure 2, the incorporated results in randomized controlled studies indicated a statistically significant increased risk for acute pancreatitis in type 2 diabetes mellitus patients who used DDP-4 inhibitors without heterogeneity with an RR of 1.67 (95% CI: 1.08–2.59; \( I^2 = 0, P = .682 \)). Random-effects meta-

---

**Table 1**

Baseline characteristic of patients in the meta-analysis.

| Author     | Year | Country | DPP-4 Events | Placebo Events | Total Events | ES (95%CI) | Research type                                      | DPP-4 |
|------------|------|---------|--------------|----------------|--------------|------------|---------------------------------------------------|-------|
| Barnett    | 2013 | UK      | 0            | 304            | 1            | 151        | RR,0.17 (0.01–4.08)                                | Saxagliptin |
| White      | 2013 | USA     | 12           | 2701           | 8            | 2679       | RR,1.49 (0.61–3.63)                                | Alogliptin |
| Hollander  | 2011 | USA     | 1            | 381            | 0            | 184        | RR,1.45 (0.06–35.40)                               | Saxagliptin |
| Scirical   | 2013 | USA     | 17           | 8280           | 9            | 8212       | RR,1.87 (0.83–4.20)                                | Saxagliptin |
| Green      | 2015 | USA     | 23           | 7332           | 12           | 7339       | RR,1.92 (0.95–3.85)                                | Saxagliptin |
| Azoulay    | 2016 | Canada  | 488          | 5165           | 7824         | 96,654     | RR,1.09 (0.86–1.38)                                | Saxagliptin |
| Garg R     | 2010 | USA     | HR,1.0 (0.7–1.3) | Retrospective cohort study | HR,1.10 (0.68–1.77) | Population-based cohort study | Linagliptin, sitagliptin phosphate, vildagliptin | Saxagliptin |
| Eurch      | 2013 | Canada  | HR,1.0 (0.7–1.3) | Retrospective cohort study | HR,1.10 (0.68–1.77) | Population-based cohort study | Linagliptin, sitagliptin phosphate, vildagliptin | Saxagliptin |
| Chou       | 2014 | China   | OR,1.04 (0.89–1.21) | Population-based nested case-control study | OR,0.98 (0.69–1.38) | Population-based matched case-control study | Sitagliptin, saxagliptin, and vildagliptin |
| Giorda     | 2014 | Italy   | OR,0.98 (0.69–1.38) | Population-based nested case-control study | OR,0.98 (0.69–1.38) | Population-based matched case-control study | Stagliptin, vildagliptin, and saxagliptin |
| Sonal Singh| 2013 | USA     | OR,2.02 (1.31–3.01) | Population-based nested case-control study | OR,2.02 (1.31–3.01) | Population-based matched case-control study | Stagliptin, saxagliptin, and vildagliptin |
| Failie     | 2013 | France  | OR,12.08 (7.3–20.0) | A case/noncase study | OR,12.08 (7.3–20.0) | A case/noncase study | Saxagliptin, sitagliptin, and vildagliptin |
| Raschi     | 2011 | Italy   | 0.31         | 2625           | 4277         | 15,6601    | OR,1.86 (1.54–2.24)                                | Saxagliptin, sitagliptin, and vildagliptin |

| CI | 95% confidence interval, DPP-4 = dipeptidyl peptidase-4 inhibitor, ES = effect size, HR = hazard ratio, OR = odds ratios, RR = relative risk. |
analysis showed that DDP-4 inhibitors were associated with an increased risk of acute pancreatitis with noticeable heterogeneity with OR = 1.45 (95% CI: 1.30–1.61; $I^2 = 96.0\%$, $P = .00$) (Fig. 3). However, similar results were not observed in cohort studies with HR = 1.06 (95% CI: 0.89–1.26; $I^2 = 0$, $P = .899$) (Fig. 4).

3.3. Publication bias

To evaluate potential bias across studies, the Begg test with funnel plot asymmetry was used to identify small study effects of the association between DDP-4 inhibitors and the risk of acute pancreatitis. The funnel plot of randomized controlled, case-control, and cohort studies shown in Figure 5, Figure 6, and

**Figure 3.** Odds ratio (OR) for the association between acute pancreatitis and DPP-4 inhibitor drugs in 5 case-controlled studies. The diamond denotes the incorporated OR. Shaded rectangles suggest the OR in each study, with sizes inversely proportional to the SE of the OR. Horizontal lines indicate the 95% confidence interval (CI). CI = confidence interval, OR = odds ratio, SE = standard error.

**Figure 4.** Hazard ratio (HR) for the association between acute pancreatitis and DPP-4 inhibitor drugs in 3 cohort studies. The diamond denotes the incorporated HR. Shaded rectangles suggest the HR in each study, with sizes inversely proportional to the SE of the HR. Horizontal lines indicate the 95% confidence interval (CI). CI = confidence interval, DPP-4 = dipeptidyl peptidase-4, HR = hazard ratios.
Figure 7, respectively, was symmetrical, which indicated a low potential publication bias ($P = .139, .253, .951$, respectively).

4. Discussion
In this meta-analysis, we analyzed the risk of acute pancreatitis associated with DDP-4 inhibitors in type 2 diabetes mellitus patients. We found evidence to suggest a marginally increased risk of acute pancreatitis associated with the use of DDP-4 inhibitor drugs in patients with type 2 diabetes in randomized controlled and case-control studies.

Since the first report involving DDP-4 inhibitors drugs (sitagliptin/metformin) and its association with acute pancreatitis published by American Food and Drug Administration,[20] numerous studies related to DDP-4 inhibitors and the risk of acute pancreatitis have been reported. Our findings are in line with previous studies.[11–14] Previously, the meta-analysis of randomized clinical trials found that DDP-4 inhibitors were associated with an increased risk of acute pancreatitis (RR = 1.57, 95% CI = 1.03–2.39).[14] Positive results were not observed in meta-analysis cohort studies. A meta-analysis involving 3 retrospective cohort studies with moderate to high risk of bias did not suggest an increased risk of pancreatitis associated with sitagliptin with an adjusted HR of 1.0 (0.7–1.3).[4] The heterogeneity within the above studies was likely a result of several methodological shortcomings, including the use of inappropriate comparator groups, small sample sizes, confounding by indication, time-lag bias, and various durations of follow-up. In randomized controlled studies, there were imbalances in case number of acute pancreatitis both in DDP-4 inhibitors groups and placebo groups. In a study conducted in the United States,[18] 24 events in DDP-4 inhibitors groups and 21 in placebo groups were reported; in another study,[17] 12 events and 4 events in DDP-4 inhibitors groups and placebo groups were recorded, respectively. In yet another study, 23 events occurred in DDP-4 inhibitors groups and 12 in placebo groups. In these studies, most cases were complicated by longstanding cardiovascular disease, which does not conform to the patients using DPP-4 inhibitors in a clinical setting.[1] Singh et al[12] reported a significantly increased risk of acute pancreatitis associated with the use of the DPP-4 inhibitor–sitagliptin in type 2 diabetes mellitus with an OR of 2.02 (95% CI:1.31–3.01). In a large number of cohort studies, compared with acarbose in diabetic patients, the authors concluded that sitagliptin was not associated with an increasing risk of acute pancreatitis even in high-risk patients.[21] A recent review reported that DPP-4 inhibitors were not associated with the risk of acute pancreatitis.[22] Previous meta-analyses[23] only focused on randomized controlled studies; however, there are some case-control or cohort studies that reported the risk of acute pancreatitis.

Although we included different types of studies in our meta-analysis, it has limitations. We failed to perform a meta-regression analysis to evaluate the potential variables because of unavailable data even though there was noticeable heterogeneity
in case–control studies. Another limitation was related to various study designs. This can account for why our analysis failed to have a unified conclusion for different study types. Even though the Begg tests with funnel plot asymmetry suggested that there was no obvious publish bias, potentially bias may be unavoidable. Besides, in this meta-analysis, the DPP-4 inhibitors had 4 different molecular structures. This also may another source of bias. It may affect the stability of results.

Our meta-analysis shows an increased risk of acute pancreatitis in DPP-4 inhibitor drugs in randomized controlled studies or case–control studies. However, meta-analysis of cohort studies failed to confirm this association with only 3 studies included. Therefore, this finding should be interpreted cautiously. There remains a cloud of uncertainty regarding the association between the risk of acute pancreatitis and DPP-4 inhibitor. Thus, to better understand the possible association, all types of original studies encompassing whole populations are urgently warranted.

References

[1] Azoulay L, Filion KB, Platt RW, et al. Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Intern Med 2016;176:1464–73.
[2] Eurich DT, Simpson S, Senthilselvan A, et al. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population-based cohort study. BMJ 2013;346:f2267.
[3] Ghazak SR, Patel DS, Shander N, et al. Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus. Curr Diabetes Rev 2010;6:410–21.
[4] Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014;348:g2366.
[5] Cohen D. Reports of pancreatitis are 20–30 times more likely with GLP-1 drugs, analysis finds. BMJ 2013;346:f2607.
[6] Kahn SE. Incretin therapy and islet pathology: a time for caution. Diabetes 2013;62:2178–80.
[7] Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349–54.
[8] Giorda CB, Picariello R, Nada E, et al. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study. Lancet Diabetes Endocrinol 2014;2:111–5.
[9] Hollandier PL, Li J, Frederich R, et al. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diabetes Vascular Dis Res 2011;8:125–35.
[10] Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232–42.
[11] Rasch E, Piccinni C, Poluzzi E, et al. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol 2013;50:569–77.
[12] Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173:534–9.
[13] Faillie JL, Babai S, Crepin S, et al. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. Acta Diabetol 2014;51:491–7.
[14] Rehmna MB, Tudrej BV, Souster J, et al. Efﬁcacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab 2017;43:48–58.
[15] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.
[16] Barnett AH, Charbonnel B, Li J, et al. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efﬁcacy. Clin Drug Investig 2013;33:707–17.
[17] White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327–35.
[18] Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317–26.
[19] Chou HC, Chen WW, Hsiao FY. Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study. Drug Safety 2014;37:521–8.
[20] American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care 2014;37(suppl 1):S14–80.
[21] Chang CH, Lin JW, Chen ST, et al. Dipeptidyl peptidase-4 inhibitor use is not associated with acute pancreatitis in high-risk type 2 diabetic patients: a nationwide cohort study. Medicine 2016;95:e2603.
[22] Mieer JJ, Nauck MA. Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia 2014;57:1320–4.
[23] Shihab HM, Akande T, Armstrong K, et al. Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: a systematic review and meta-analysis of randomized trials. World J Metaanal 2015;3:254.